Devices and methods for screening disease vectors
By designing a self-contained system, a device is used to break up disease vectors using mechanical force and combined with fluorescence immunoassay or colorimetric assay, which solves the problems of delayed diagnosis of tick-borne diseases and user risks, and achieves rapid and safe screening for disease vectors.
Patent Information
- Application Number
- CN202580027577.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-08-30
- Filing Date
- 2025-02-19
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies suffer from diagnostic delays in the diagnosis of tick-borne diseases and other vector-borne diseases, and existing devices or methods require specialized equipment and technical knowledge, and pose a risk of user contact with pathogens.
A device for a self-contained system, including a container, a cap, and a breaking element, is designed to apply mechanical force to disease vectors within the self-contained system to prevent disease vectors from escaping and to screen pathogens by fluorescence immunoassay or colorimetric assay.
It enables rapid and safe fragmentation of disease vectors in the home environment, reducing operational difficulty and user exposure risks, improving diagnostic efficiency, and reducing diagnostic delays.
Smart Images

Figure CN123125477A_ABST
Abstract
Description
Technical Field
[0001] One or more aspects relate to devices and methods for screening disease vectors. Background Technology
[0002] Tick-borne diseases and other vector-borne diseases are a serious and growing problem, with positive diagnoses of Lyme disease now recorded in every state in the United States. Shorter diagnosis times for these diseases are associated with higher treatment success rates. Currently, diagnostic tests for Lyme disease have a delay of several weeks because it takes time for the human immune system to produce enough antibodies to be detected by current diagnostic tests. Summary of the Invention
[0003] According to one or more aspects, an apparatus for treating disease vectors for screening is disclosed. The apparatus may include: a container defining a breakage recess configured and arranged to receive disease vectors for treatment; a cap configured to create a self-contained system when securely engaged with the container and not reopened, while remaining rotatable relative to the container to facilitate treatment of disease vectors within the self-contained system; and a breakage element extending from the cap into the container and configured to engage with the breakage recess via rotation of the cap to treat the disease vector.
[0004] In some respects, dealing with disease vectors may involve at least partially breaking them down. A self-contained system can be configured to apply mechanical forces to the disease vector. A self-contained system can be configured to apply mechanical forces to the disease vector along two axes.
[0005] In some aspects, at least one of the breaking recess and the breaking element defines a surface roughness to facilitate the treatment of disease vectors. The breaking element may include a breaking head connected to the breaking tool. The breaking element may include one or more contact portions to facilitate the treatment of disease vectors.
[0006] In some aspects, the container is further configured to receive fluid to facilitate screening for treated disease vectors. The device may further include a fluid chamber. The fluid chamber may be contained within a lid or container.
[0007] In some aspects, the device may further include a separation mechanism to facilitate downstream disease vector screening.
[0008] In some respects, the device can be connected to a assay device. In at least some respects, the assay device does not involve DNA-based assays. The device can be configured to receive assay strips to facilitate disease vector screening.
[0009] In some aspects, screening for disease vectors may involve fluorescent immunoassays. In others, the assay device may be a colorimetric assay. Screening for disease vectors may involve nanoparticle (NP)-labeled antibodies and / or antigen-based sensing. In some aspects, the assay device uses both anti-Brepharosphritis polyclonal antibody and anti-OspA antibody. In some specific, non-limiting aspects, the concentration of the signal antibody may be approximately 40 μg / mL.
[0010] In some respects, the device is a tick screening device designed for home use.
[0011] According to one or more aspects, a lateral chromatographic assay (LFA) for screening disease vectors is disclosed. The LFA may contain an anti-Breorhynchus burgdorferi polyclonal antibody and an anti-OspA antibody.
[0012] A kit is disclosed according to one or more aspects. The kit may include a device for treating disease vectors as described herein.
[0013] In some aspects, the kit may further include a buffer solution source. The kit may further include a labeled antibody source. The labeled antibody source may include a sealed dropper containing a buffer solution of the labeled antibody.
[0014] In some aspects, the kit may further include an assay device. The assay device may be an antibody- and / or antigen-based sensing assay. The assay device may be a fluorescence immunoassay. The assay device may be a colorimetric assay. In some aspects, the assay device may be a lateral chromatography (LFA) assay. The assay device may involve an LFA test strip.
[0015] In some aspects, the assay device can use both anti-Brephaerocephalus polyclonal antibody and anti-OspA antibody. The assay device can use anti-Brephaerocephalus polyclonal antibody, anti-OspA antibody, and anti-OspC antibody. In a non-restrictive aspect, the concentration of the signal antibody-AuNP present in the LFA sample buffer can be approximately 4 μg / mL. The antibody-AuNP conjugation ratio of the signal antibody can be approximately 40 μg / mL per 10 OD.
[0016] In some respects, the assay device can screen for multiple vector-borne diseases in a single sample using a unique combination of capture-signal antibodies against each of the bacteria being tested.
[0017] In some respects, the LFA test strip may be defined by an average pore size of at least about 6-12 μm. In some non-limiting respects, the LFA test strip does not include a conjugate pad on which a signal antibody is immobilized. The signal antibody may be present in a buffer solution.
[0018] In some respects, the assay can screen for anaplasmosis (Phaseolus phagocytosus).Anaplasma phagocytophillium ) or babesiidae (a type of volcano) Babesia microti Proteins related to ).
[0019] In some respects, the measurement can be based on aggregation.
[0020] In some respects, the kit may further include a base configured to stabilize the container during treatment of disease vectors.
[0021] In some respects, the kit may be designed for home use.
[0022] In some respects, the kit can be specifically a Lyme disease screening kit.
[0023] According to one or more aspects, a method for screening disease vectors is disclosed. The method may involve the steps of treating the disease vector using an apparatus as described herein to produce a solution, and subjecting the solution to assay to assess the presence or absence of a pathogenic agent.
[0024] In some respects, dealing with disease vectors can involve applying mechanical forces along two axes.
[0025] In some respects, the assay may not be based on DNA.
[0026] In some respects, assays can screen for target proteins associated with pathogenic pathogens. In non-restrictive respects, pathogenic pathogens can be associated with Lyme disease, babesiosis, ehrlichiosis, Rocky Mountain spotted fever, anaplasmosis, Southern Tick-Associated Rash Illness, Tick-Borne Relapsing Fever, and tularemia.
[0027] In some respects, the target protein can be associated with Lyme disease-causing bacteria. The target protein can be associated with Borrelia burgdorferi. The assay can target Borrelia burgdorferi proteins. In some non-limiting respects, the assay can target outer surface protein A (OspA). In other respects, the assay can target tick salivary gland proteins.
[0028] In some embodiments, the assay can be an antibody- and / or antigen-based sensing assay. The assay can be a lateral chromatography assay (LFA). In other embodiments, the assay can be an aggregation-based assay.
[0029] In some respects, the assay can further screen for second target proteins associated with second pathogenic bacteria.
[0030] Depending on one or more aspects, a lateral chromatographic assay (LFA) for screening disease vectors can be any LFA as described herein.
[0031] In some non-restrictive aspects, LFA can screen for target proteins associated with Lyme disease pathogenic bacteria.
[0032] The present invention was developed in response to the current state of the field, particularly addressing the problems and needs that have not been fully or completely resolved by currently available disease vector disruption devices or screening methods.
[0033] Therefore, one object of the present invention is to provide a disease vector disruptor, which may include, but is not limited to, ticks, multiple ticks or small pests, the device being able to fully or completely disrupt the disease vector, enabling effective further testing of the released components or contents of the disease vector.
[0034] One object of the present invention is to demonstrate an apparatus for breaking down disease vectors, which can effectively break down disease vectors in significantly less time (e.g., 50% or more less) than prior art breaking down apparatuses or methods.
[0035] Another object of the present invention is to provide an apparatus for breaking up disease vectors that requires a lower knowledge threshold for the user than the operation of existing breaking devices or methods such as micromixers, “bead mill” vials or centrifuges.
[0036] Furthermore, an object of the present invention is to provide a device for safely breaking up disease vectors, which requires significantly less force than prior art devices such as those using a fixed cap and rotational action, thus significantly reducing the risk to the user due to improper use of prior art devices or methods.
[0037] Furthermore, the object of the present invention is to provide a device for breaking up disease vectors that prevents the user from coming into contact with the disease vector or one or more pathogens carried by the disease vector after the disease vector has been placed in the device, such as by using a closed container with a lid that is not reopened to form a self-closing system.
[0038] Finally, an object of the present invention is to provide a device for breaking up disease vectors that is quiet and portable, allowing disease vectors to be broken up in place without requiring access to specific equipment or a place to place such equipment, as is the case with prior art devices or methods.
[0039] One feature of the present invention, enabling the achievement of the above-mentioned objectives, is a crushing or grinding element comprising a crushing head and a crushing recess connected to a crushing tool, between which a disease medium is placed for crushing. In a preferred embodiment, the disease medium placed in the crushing recess is clamped between the crushing recess and the crushing head. The crushing head rotatably contacts the crushing recess and is configured such that the contact portion between the crushing head and the crushing recess, under the application of mechanical force, will sufficiently or completely crush the disease medium, thereby allowing extraction and release of the contents of the disease medium. The contact portion between the crushing head and the crushing recess may also include a surface design to aid in crushing or grinding the disease medium under mechanical force applied to the outside of the cap and / or container.
[0040] An exemplary feature of the invention that enables the above-mentioned objective is a breaking surface on a breaking recess, a breaking head, or both, which is configured with a rough surface or a surface having a pattern of alternating recesses and protrusions, between which disease vectors will be sandwiched and subjected to mechanical force for breaking.
[0041] The container that houses the fractured recess at its base can be a single integral component or several separate components. The disease vector will be placed in the fractured recess within the container, and the container should be designed to make it difficult for the disease vector to escape once placed inside.
[0042] The container will be fitted onto a cap with a slot designed to form a self-sealing system, whereby the cap cannot be reopened after being placed on the container to prevent escape of disease vectors and to minimize the risk of contact between the user and the disease vector after it has been placed in the container. A crushing tool with a crushing head may or may not be attached to the cap. The slot on the cap may be sealed with a membrane, film, or suitable covering to ensure the system is self-sealing, thereby preventing aerosolization of the contents of the device or any contents of the device from escaping into the environment during treatment. Test strips can then be inserted at subsequent time points, for example via a cover / film that punctures the slot, to facilitate screening tests for treated disease vectors. The self-sealing system will also be safe such that any mechanical forces applied to the inside or outside of the container and cap, such as shaking, pressing, pushing, crushing, or grinding, will not cause any leakage of contents (e.g., fluid or fragmented disease vector portions or any combination of both).
[0043] A fluid may be contained in or introduced into the cap, container, or any other component of the rupture device to allow it to come into contact with the extracted components of the ruptured disease vector, thereby enabling a test reaction to detect the presence or absence of one or more pathogens carried by the disease vector. The test reaction can be carried out via a test strip or test device that can be inserted into a slot on the cap, such that a portion of the test strip can come into contact with the mixture of the fluid and the ruptured disease vector (fluid-vector mixture) and trigger a test reaction that indicates the presence or absence of one or more pathogens carried by the disease vector.
[0044] The disruption device may include a filtration device or membrane or any such separator system that will allow the disruption of a portion of the disease vector to be separated from the target contents or fluid of the disease vector containing one or more pathogens, in order to allow for further testing of the extracted contents of the disease vector.
[0045] The disruption device may also include mechanisms, such as a combination of connectors, notches, channels, microfluidic channels or chambers, or any such similar design features, to allow the disruption of the disease vector-fluid solution to be accessed by one or more components of a further testing device, such as an assay system, to detect the presence of one or more pathogens.
[0046] A disease vector disruptor can be used alone to disrupt disease vectors or combined with another testing device to allow the detection of one or more pathogens carried by the disease vector. The disease vector disruptor can be made of one or any combination of any materials (in non-limiting examples, resin or plastic).
[0047] Various methods for treating disease vectors for screening have been disclosed.
[0048] Various assay methods for screening treated disease vectors were also disclosed.
[0049] Various test strips related to assays used for screening treated disease vectors have been disclosed.
[0050] Various assay techniques for screening treated disease vectors were also disclosed.
[0051] Various kits for preparing and screening disease vectors were also disclosed.
[0052] These and other objects and features of the invention will become more apparent from the following description and appended claims, or may be learned by practicing the invention as set forth below. Attached Figure Description
[0053] To obtain the above and other advantages and objects of the invention, a more detailed description of the invention, briefly described above, will be given by reference to the specific embodiments illustrated in the accompanying drawings. It should be understood that these drawings depict only typical embodiments of the invention and are therefore not intended to be considered as limiting its scope; the invention will be described and explained with additional specificity and detail using the drawings listed below.
[0054] Figure 1 This is a perspective view of the device of the present invention, wherein the crushing tool and the crushing head are in contact or closed positions with the crushing recess and the cover is closed on the container to form a self-closing system. Figure 2 This is a perspective view of the device of the present invention, an exploded perspective view in which the crushing tool and the crushing head are in the open position, wherein the crushing tool and the crushing head have not yet contacted the crushing recess, and the cover has not yet closed onto the container to form a self-closing system. Figure 3 This is a side view of the device of the present invention, which is substantially the same as... Figure 2 The apparatus shown is the same, wherein Figure 3 The device is in the open position, meaning the crushing tool and crushing head have not yet contacted the crushing recess, and the cover has not yet been closed onto the container; Figure 4 A schematic diagram of the device of the present invention with a lateral tomographic detection strip or test strip inserted is shown, illustrating the use of the device in sensing tests; Figure 5 Various schematic diagrams of the cover of the device of the present invention from different angles and viewpoints are presented; Figure 6 Various schematic diagrams of the container of the device of the present invention are presented from different angles and viewpoints; Figure 7 A schematic diagram of a fluorescence immunoassay screening method according to one or more implementation schemes is presented; Figure 8 Presented with Figure 7 A schematic diagram of a mobile application used in conjunction with a fluorescence immunoassay screening method; Figure 9 Schematic diagrams of various labeled antibody and / or antigen-based sensing methods for screening disease vectors, according to one or more embodiments, are presented; Figure 10-13 Schematic diagrams of lateral chromatographic assay (LFA) test strips according to various implementation schemes are presented; and Figure 14-15 The data discussed in the accompanying examples are presented. Detailed Implementation
[0055] This invention relates to an improved apparatus for breaking down disease vectors to extract their contents, the disease vectors including, but not limited to, ticks, multiple ticks, or one or more other small pests. More specifically, the apparatus is a tick or pest crusher that enables ticks, multiple ticks, or pests to be broken down or partially separated to extract specific contents of the ticks or pests for further reactions to be performed on the extracted contents, thereby enabling the detection of the presence or absence of one or more pathogenic pathogens.
[0056] Currently, testing for pathogens in disease vectors (such as ticks or small pests) requires a laboratory testing environment where the disease vector must be homogenized for a test reaction to determine if the pathogen is carried by the vector. This is typically accomplished using specialized equipment or techniques to homogenize the disease vector. However, there are no readily available mechanical crushers that would allow users to instantly break up ticks, small pests, or disease vectors, where the crusher is designed to place the disease vector into the crusher and apply mechanical force to break it up.
[0057] Disruption of disease vectors (including, but not limited to, ticks, multiple ticks, or small pests) may involve causing damage to the exterior of the disease vector, separating some or all of the exterior of the disease vector from the internal contents of the tick (i.e., the disease vector), and / or breaking the disease vector to allow exposure of its internal components.
[0058] Existing test kits involve using a pointed rod within a container to allow users to manually apply force to the disease vector, causing damage to its exterior for further testing. However, this manual breaking may not effectively release the vector's contents, there is a risk of vector escape if the container is too shallow, and results vary depending on the size of the user and the vector.
[0059] In laboratory settings, there are devices such as micromixers or “bead mill” vials, which consist of one or more beads in a vial that is violently shaken in a device such as a high-power centrifuge to pulverize disease vectors. However, such pulverization methods require the operator to have technical knowledge of operating the machinery, the necessary components of the pulverization reaction, and access to specialized equipment.
[0060] According to one or more embodiments, an apparatus for breaking down disease vectors, which may include, but are not limited to, ticks, various ticks or other small pests, is disclosed. The apparatus can fully or completely break down the disease vector, allowing for further testing of the extracted contents of the disease vector.
[0061] According to one or more embodiments, an apparatus for breaking down disease vectors is also disclosed, which can effectively break down disease vectors in significantly less time than prior art breaking devices or methods.
[0062] According to one or more embodiments, an apparatus for breaking up disease vectors is disclosed, which requires a lower knowledge threshold for the user than that required by current prior art breaking up devices or methods.
[0063] According to one or more embodiments, an apparatus for safely breaking up disease vectors is disclosed, which requires significantly less force than prior art devices, thus significantly reducing the risk to users due to improper use of prior art devices or methods.
[0064] According to one or more embodiments, a device for breaking up disease vectors is disclosed, which prevents a user from coming into contact with the disease vector or one or more pathogens carried by the disease vector after the disease vector has been placed in the device.
[0065] According to one or more embodiments, a device for breaking up disease vectors is disclosed, which is quiet and portable, allowing disease vectors to be broken up in place without requiring access to specific equipment or a place to place such equipment, as is the case with prior art devices or methods.
[0066] There is a need for an improved disease vector disruptor that overcomes or avoids the problems described above as disclosed in this paper.
[0067] There is also a need for assays to effectively and efficiently screen for treated disease vectors, as disclosed herein.
[0068] Further kits are still needed to facilitate the handling and screening of disease vectors as disclosed in this article.
[0069] Device: This invention relates to an improved apparatus for the mechanical treatment of disease vectors, including but not limited to ticks, various tick species, or small pests. More specifically, the apparatus is a disease vector disruptor that enables the disease vector to be broken down or partially separated to extract specific contents of the disease vector for further testing reactions to be performed on the extracted disease vector contents, thereby detecting the presence or absence of one or more pathogenic pathogens. In at least some embodiments, treatment of the disease vector can make any relevant target bacteria (and associated surface proteins) available for effective screening. The target bacteria and associated surface proteins may be associated with one or more biological systems of the disease vector and can be used for screening through adequate treatment of the disease vector as described herein.
[0070] According to one or more embodiments, the device is operable to apply sufficient torque and / or shear force to grind target media of any size and type. The device can be effectively operated by any user across a wide range of ages, strengths, and abilities.
[0071] According to one or more implementation schemes, the device achieves effective exoskeleton rupture.
[0072] According to one or more embodiments, the device utilizes controlled shear force application to ensure sufficient destruction of the pathogen. The determination of the optimal shear force can depend on a variety of factors, including but not limited to the nature of the disease vector's exoskeleton, the user's strength and hand strength (e.g., age dependence), and the conversion of the applied force into shear stress. The shear force required to break the tick's exoskeleton depends on hydration, tick species, and maturity.
[0073]
[0074] In some implementations, the abrasive surface creates a high-friction interface to induce shear forces between 50 and 1000 N, effectively fracturing the exoskeleton of disease vectors such as ticks. The fracturing mechanism allows users with varying hand strengths to generate sufficient pressure to achieve the necessary shear stress of 5–50 MPa.
[0075] According to one or more embodiments, the device utilizes optimized abrasive surface roughness to enhance the mechanical adhesion of the abrasive to the target medium while maintaining durability and efficiency. In some embodiments, the device may be characterized by a surface roughness of approximately 30-100 μm Ra.
[0076] The following are non-limiting recommendations based on grinding and crushing mechanisms:
[0077] Ra 20–75 µm: equivalent to coarse sandpaper (40-60 grit) or a rough-finished surface.
[0078] Rz 100–400 µm: Ensures strong material interactions.
[0079] Rt 150–600 µm: Allows for effective deformation of the tick exoskeleton.
[0080] According to one or more embodiments, the device utilizes a defined shear stress threshold to match the biomechanical properties of the exoskeleton of the target disease vector. In some embodiments, a shear stress threshold of approximately 5–50 MPa may be applicable.
[0081] Figure 1-3The main components of the device shown include a cover A, a container B, a crushing tool C, a crushing head D, a crushing recess E, a contact portion F, a crushing surface G, and a slot H. Other design components may include, but are not limited to, an additional connecting mechanism I, a fluid chamber K, and a filtration mechanism K. Design components I, J, and K are not specified in the provided text. Figure 1-6 As shown in the image.
[0082] Figure 1 A perspective view of the device in either the contact or closed position is shown, wherein the crushing head D is connected to the crushing tool C and contacts the crushing recess E. The disease medium is placed within the crushing recess E and sandwiched between the crushing head D and the crushing recess E. Additional design features and mechanisms located on the sides of the crushing head D and the crushing recess E have contact portions F, which, under mechanical force applied to the exterior of the cap A or container B, facilitate the grinding of the disease medium on the crushing surface G. The cap A is rotatably fitted onto the container B, forming a self-closing system, wherein the cap A remains rotatable, allowing mechanical force to be applied to the exterior of the cap A or container B to rotatably move the crushing head D and the crushing recess E within the device. The cap A also has a slot H into which a lateral chromatography assay or test strip can be inserted to contact the suspension or fluid-medium mixture in the container B for testing. The slot H may be covered by a membrane, film, seal, or cover that seals the entire system and prevents the contents of the device from aerosolizing or escaping into the environment until the test strip has been inserted into the slot for testing. The self-sealing system is designed to be safe such that after the cap A has been fitted into the container B, any mechanical forces applied to the inside or outside of the container and / or cap, such as shaking, pressing, pushing, breaking, or grinding, will not cause any leakage of contents (e.g., fluids or fragmented disease-carrying parts, or any combination of both).
[0083] Figure 2 An exploded perspective view shows the crushing tool C and crushing head D in the open position relative to the crushing recess E. The crushing tool C is connected to the cover A and the crushing recess E, located within the container B. Figure 2 In the middle, the crushing tool C and the crushing head D have not yet come into contact with the crushing recess E, and the cover A has not yet closed onto the container B.
[0084] Figure 3 This is a side view of the crushing device in the open position, similar to... Figure 2 Side view. Figure 3 A crushing tool C and a crushing head D are shown connected to a cover A, and can be made of any material (in a non-limiting example, resin or plastic). The various components of the crushing tool C, the crushing head D, and the cover A may or may not be made of the same material. Figure 3The diagram also shows the breakage recess E and the breakage surface G located within container B. The disease vector should be placed within the breakage recess E, sandwiched between the breakage surface G and the breakage head D. When a downward force is applied to the cap A to close it onto container B, the disease vector should be sandwiched between the breakage head D and the breakage surface G, or within the contact portion F. When mechanical force is applied to the outside of cap A or container B, the disease vector / tick should be broken or crushed more effectively. A suspension or fluid-vector mixture is then produced as a result of the mechanical force applied to the disease vector / tick, and the suspension or fluid-vector mixture can subsequently be tested through a test strip inserted through the slot H in cap A. The various components of container B, breakage recess E, breakage surface G, and contact portion F can be made of any material (in non-limiting examples, resin or plastic), and the various components may or may not be made of the same material.
[0085] According to one or more non-limiting embodiments, container B includes a convex conical base at a center approximately 0.1875-0.5 inches deep above the container base (reference plane). A concave conical surface is present on the crushing head D, which matches the geometry of container B to provide a crushing surface upon rotation. This crushing surface on the crushing head D can be smooth or rough (0-25 µm). Furthermore, upon rotation, the conical surface is designed to guide tick / fly particles to teeth spaced approximately 0.093 inches apart and 0.025 inches deep around the periphery of the container's conical geometry to provide further crushing upon rotation. The crushing head D has a reduced number of teeth primarily for capturing ticks and guiding them to the outer teeth on the contact portion F and the crushing recess E. The tooth pitch, depth, angle, and spacing of the crushing tool C, the crushing head D, the contact portion F, and the crushing recess E can be modified to optimize crushing.
[0086] The purpose of handling disease vectors is to fully extract and release their contents, enabling further testing of the released vector components or contents and detecting the presence or absence of one or more pathogenic pathogens. Therefore, other components should be incorporated into the design, including but not limited to additional connecting mechanisms I, fluid chamber J, and filtration mechanisms K. Design components I, J, K, and other potential design components are not included in... Figure 1-6 However, it can be implemented in a crushing device or related kit to enhance the accuracy, reliability, and visible response of further tests performed on the crushed disease vector components.
[0087] The connecting mechanism I may be part of the design of either lid A or container B, connecting to lid A or container B and allowing the crushing device to be connected to a further testing system, which may include, but is not limited to, an assay system or any other test that will allow the detection of the presence or absence of one or more pathogenic pathogens in the fluid, the crushed disease vector portion, or any combination of both. The fluid chamber J may be housed within lid A or container B, or located externally to the crushing device. The fluid chamber J should contain a fluid that will contact the crushed disease vector portion to form a suspension or fluid-vector mixture, which may allow the detection of the presence or absence of one or more pathogenic pathogens in the suspension or mixture, whether by a visible reaction within the fluid, suspension, or fluid-vector mixture itself, or by entry into a further testing system, which may include, but is not limited to, an assay system that triggers a visible reaction in the further testing system.
[0088] The filtration unit K can be housed within a cover A or container B, or located externally to the crushing device. The purpose of the filtration unit is to sieve larger fragments of the disease vector from the fluid, suspension, or fluid-media mixture to produce a subsequent fluid, suspension, or fluid-media mixture that will provide a more reliable, accurate, and visible response upon contact with the assay system. The filtration unit will be used after the fluid has come into contact with and mixed with the fragmented disease vector components to produce the subsequent fluid, suspension, or fluid-media mixture. These other design components I, J, K, and other potential design components can be made of any material (in non-limiting examples, resin or plastic), and the various components may or may not be made of the same material.
[0089] Exemplary disease vector treatment devices / crushers / homogenizers and storage devices include, but are not limited to, containers having tools or designs that allow the placement of pests or multiple pests into the container; crushing / grinding elements; and lids or covers for creating a self-closing system. The container and lid function to provide a volume in which one or more pests are contained within the self-closing system and cannot escape. The crusher / grinder tool functions to cause damage to the exterior of the tick, separating some or all of the tick's exterior from its internal contents, and / or crushing the tick to allow exposure of its internal components. The device will also have mechanisms for introducing fluid into or containing a grinding chamber. It will also have a manner that allows the crushed tick-fluid solution to be accessed by an assay system to detect the presence of *Borrelia burgdorferi*. The crusher / homogenizer and storage device can be made of any material (in non-limiting examples, resin or plastic). The crusher / homogenizer and storage device can be used alone or in combination with an assay for screening for the presence of one or more pathogenic pathogens.
[0090] According to one or more embodiments, the cover will close the crushing device to form a self-closing system in which disease vectors will be stored / contained and external mechanical force can be applied to aid in the crushing of disease vectors.
[0091] According to one or more embodiments, the container will contain the disease vector and form a self-closing system when the lid is closed, so that the disease vector will not be able to escape, and mechanical force can be applied to its exterior to help break the disease vector. This will also allow mechanical force to be applied to the disease vector contained in the container to partially or completely break or shatter it.
[0092] According to one or more embodiments, the crushing tool will be connected to the cover and the crushing head, which will allow the extension of the crushing head to contact the crushing recess.
[0093] According to one or more embodiments, the crushing head will be an extension of the crushing tool and designed to rotatably assemble with and contact the crushing recess, wherein the mechanical force applied to the cover will allow it to partially or completely crush or fragment the disease vector.
[0094] According to one or more embodiments, a disease vector is placed therein and will be connected to a breakage recess of the container, which will be designed to be rotatably fitted and in contact with the breakage head, wherein the mechanical force applied to the container will allow the disease vector to be partially or completely broken or fragmented.
[0095] According to one or more embodiments, the contact portion extends from the crushing head and the crushing recess and is located at the edge of the crushing head and the crushing recess, wherein the disease medium can be trapped within the contact portion to help grind the disease medium on the crushing surface or in the contact portion under mechanical force applied to the outside of the cap or container.
[0096] According to one or more embodiments, the breaking surface will be located on the breaking recess, wherein the disease vector will be sandwiched between the breaking head and the breaking recess, the two components will contact each other when the lid is fully closed over the container, and the disease vector will be completely or partially broken or fragmented when mechanical force is applied to the outside of the lid or container.
[0097] According to one or more implementation schemes, the connecting mechanism can connect the crushing device and its contents to a further testing system.
[0098] According to one or more embodiments, the fluid chamber may contain fluid that will come into contact with fragmented disease vector portions to form a fluid, suspension, or fluid-vector mixture, and the fluid may be contained within the crushing device or introduced from the outside.
[0099] According to one or more embodiments, the filtration unit can screen out larger fragmented disease vector components from a fluid, suspension, or fluid-media mixture for use after the fluid has come into contact with the fragmented disease vector components.
[0100] The technology functions as a self-enclosed system in which ticks or multiple ticks can be placed and captured for crushing.
[0101] The container is designed to allow ticks to be placed inside and to allow the ticks to come into contact with the broken surface. To form a self-closing system, a lid or cover can be fitted onto the container after the ticks have been contained inside.
[0102] According to one or more embodiments, a one-way snap-on cap can be implemented. The one-way snap-on cap will allow the cap to close onto the container, but will not allow the two components to separate once the cap is in place. The one-way snap-on cap can still rotate freely relative to the container after it is in place to facilitate the handling of occluded disease vectors.
[0103] The crushing tool may or may not be attached to the cap or other parts of the technology. The crushing tool should be designed within a self-closing system in such a way that it can apply sufficiently high surface pressure to the tick to cause damage to the outside of the tick and / or grind / crush the outside of the tick so that internal fluids can be released, or simply homogenize the entire tick.
[0104] The technology may include, but is not limited to, designs that allow for the containment of solutions, and may include filtration devices or membranes or any such separator systems that will allow the separation of dissociated or fragmented portions of the tick from the target fluid or specific contents of the tick containing the target pathogen for further assaying of the extracted contents. Connection connectors, channels, combinations of microfluidic channels or chambers, notches, or any such similar design features may be present in the technology to connect it to one or more components of the test kit. The technology may be made of any material.
[0105] The technology includes, but is not limited to, containers with tools or designs that allow the placement of disease vectors or multiple disease vectors into the container; crushing / grinding elements; and lids or covers for creating a self-closing system. The container and lid function to provide a volume in which one or more pests are contained within the self-closing system and cannot escape. The crusher / grinder tool functions to cause damage to the exterior of the tick, separating some or all of the tick's exterior from its internal contents, and / or crushing the tick to allow exposure of its internal components. The device will also have a mechanism for introducing fluid into or containing a grinding chamber. It will also have a manner that allows the crushed tick-fluid solution to be accessed by an assay system to detect the presence of *Borrelia burgdorferi*. The technology can be made of any material (in non-limiting examples, resin or plastic). The technology can be used alone or in combination with assays that can screen for the presence of pathogenic pathogens.
[0106] According to one or more embodiments, a breaker for disease vectors, including but not limited to ticks or small pests, is disclosed. The breaker applies pressure to the disease vector to enable a user to quickly and safely break the tick or small pest, preventing escape once placed in the device. One or more disease vectors are held within a self-closing system having a container secured by a cap configured to snap shut. The cap is configured as an extended abrasive element comprising a breaker head and a breaker recess for breaking the disease vector. The breaker head rotatably contacts the breaker recess. Fluid is contained or introduced into the disease vector breaker, and it may include connecting channels for connecting the fluid to a separate testing device.
[0107] According to one or more embodiments, the device may generally have a structure and / or function similar to a salt or pepper grinder, but the device may have two axes in which disease vectors are ground. The device will have “upper and lower” grinding surfaces, with two hard disks vertically crushing and grinding ticks. The tick, also as it is squeezed downwards and away from the center, will begin to be ground by the “outer-inner surface” of the outer edge of the rotating disk and the inner surface of the entire container.
[0108] Prior to treatment, the ticks to be crushed typically exhibited an average particle size (D50) of 5–9 mm (nymph to adult), indicating a relatively coarse structure. After the improved mechanical treatment, the D50 value decreased to 100–500 µm (0.1–0.5 mm), demonstrating a particle size refinement of at least tenfold. This reduction in average particle size increases the surface area to volume ratio, resulting in improved solubility, better mixing properties, and enhanced bioavailability. By achieving finer particle sizes with higher crushing efficiency, the method demonstrates a superior approach to mechanical treatment with enhanced performance characteristics.
[0109] According to one or more embodiments, the abrasive surface is designed to be rough to facilitate fragmentation. The dimensions of the abrasive surface are deliberately selected to ensure the fragmentation of black-legged ticks, which are approximately 1.5 mm in size or the size of a sesame seed nymph. The abrasive surface and / or other components of the device for treating disease vectors can be customized to facilitate and optimize specific use cases.
[0110] According to one or more embodiments, the buffer solution can be introduced into the container along with the test medium before the container is closed and mechanical rotation / grinding force is applied. The buffer solution can typically be used to release bacteria from homogenized ticks, which are then allowed to flow through, for example, lateral chromatography strips discussed herein.
[0111] In some implementations, the slot in the device may have a thin membrane / film or a seal that can be removed for insertion of the LFA. Alternatively, the LFA strip may pass through the slot with a membrane / film.
[0112] According to one or more embodiments, the LFA test strip will come into contact with the underlying broken tick+ solution suspension, and the test line will appear above the cap, in the portion of the test strip exposed for user observation.
[0113] Depending on one or more embodiments of the operation, the user may locate the tick or other disease vector. If the disease vector is attached and / or engorged, it may be removed from the subject. For example, the disease vector may be in nature, on clothing, on a pet, or on human skin. The tick is then dripped into the open lower half of the crushing container, and sample buffer is poured into the open crushing container using a dropper or similar fluid container. The top cap is then closed onto the bottom cap and "clicks" into place. The two halves of the container are then twisted in opposite directions until the tick has been properly treated. Treatment may involve causing injury, dismemberment, or homogenization. The treated disease vector may then undergo an assay for screening. In some non-limiting embodiments as described herein, the treated disease vector may undergo a lateral chromatographic assay (LFA). The LFA may be inserted through the top of the container to access the treated tick / buffer sample and allowed to stand for a period of time, such as 20 minutes. Alternatively, the LFA may be inserted through the slot into the top of the container after the user removes the sticker seal or other protective covering above the slot to allow insertion of the LFA strip. The LFA may typically protrude partially from the top of the container. If a visible line is found on the part of the LFA that extends out of the container after 20 minutes, Borrelia burgdorferi is present in the broken tick.
[0114] Various components of the device and / or related kit may depend on or be influenced by the relevant assay technology. For example, in embodiments involving LFAs, the sample pad on the LFA will act as a sufficient filter, making additional filter assemblies as described herein unnecessary in the design. Similarly, the processing device may provide sufficient support, eliminating the need for an additional stabilizing base.
[0115] According to one or more embodiments, the kit may include the following elements: two halves of an open, unused tick breaker container, e.g., a container and a lid / cap; a dropper or similar fluid container containing sample buffer that will be squeezed into the tick breaker along with the tick; and any assay, such as a lateral chromatography assay (LFA) strip. The LFA strip may be in sterile packaging.
[0116] According to one or more alternative embodiments, the disease vector can be placed in a flexible vial. The user can repeatedly squeeze the vial until the tick is fully broken. The flexible vial can be filled with a solution buffer (e.g., PBS) during treatment of the disease vector. Alternatively, the buffer solution can be added after treatment. Figure 4 This provides an overall explanation of the method.
[0117] Screening technology: To shorten treatment time, rather than waiting for the bitten person to develop antibodies in response to the infection, the disease vector that carried the bite, such as, but not limited to, ticks, biting flies, and mosquitoes, can be tested for the presence of pathogenic pathogens or microorganisms, such as, but not limited to, bacteria, viruses, or parasites. While any disease vector can be screened to detect any pathogens or microorganisms carried by the vector according to the various embodiments disclosed herein, a non-limiting example that can be used throughout for the sake of simplicity is a tick carrying the Lyme disease pathogen Borrelia burgdorferi.
[0118] According to one or more implementation schemes, disease vectors can be screened to detect tick-borne diseases, such as, but not limited to, Lyme disease, erythrozoonosis, babesiosis, and anaplasmosis.
[0119] According to one or more implementation schemes, disease vectors can be screened to detect one or more diseases or pathogenic antigens selected from the group consisting of: spirochetes, elchiobacteria, anaplasma, Rocky Mountain spotted fever, rickettsia, tularemia, babesiosis, Heartland virus, Bourbon virus, Colorado tick-borne fever, Bovasan virus disease, relapsing fever, Mediterranean spotted fever, Rickettsia kesinae, tick-borne encephalitis (TBE virus), neo-Ehrlich disease, and Lyme-like disease.
[0120] According to one or more implementation schemes, disease vectors can be screened to detect a group of diseases, such as a group of diseases associated with a specific geographic area.
[0121] According to one or more embodiments, screening devices such as, but not limited to, lateral chromatographic assays (LFA) are operable to effectively detect one or more pathogens or microbial agents disclosed herein, as well as one or more other diseases that may be associated with the target disease vector. In some embodiments, the screening device may provide a screening panel, such as a regional screening panel.
[0122] According to one or more implementation schemes, the apparatus, kits, and methods can be used to test for the presence of disease vectors such as ticks, and for diseases such as Lyme disease.
[0123] According to one or more embodiments, screening devices can be performed in the field of Lyme disease detection. Currently, if a user finds a engorged tick on their body, pet, or other person, they have limited methods to determine whether the biting tick carries the Lyme disease-causing bacterium Borrelia burgdorferi. The primary method for screening ticks for Lyme disease detection is currently to mail the tick to a laboratory and wait for the laboratory to mail back the tick's DNA results. There is currently no publicly available device that can screen found ticks for the presence of Borrelia burgdorferi without requiring samples to be mailed to a laboratory for DNA testing. According to one or more embodiments, it is possible to test found ticks for the presence of target pathogens or microorganisms without requiring samples to be mailed to a laboratory.
[0124] Routine tests for diagnosing Lyme disease include polymerase chain reaction (PCR), an expensive and time-consuming process. Screening techniques based on DNA assays that are not performed in a laboratory for similar tests can be implemented, depending on one or more implementation schemes.
[0125] Various proteins that support the persistence of Borrelia burgdorferi, leading to Lyme disease, are known to those skilled in the art. These proteins include Borrelia burgdorferi proteins or tick salivary gland proteins. Borrelia burgdorferi proteins: lipoproteins, outer surface proteins (Osps), BB0323, BBA52 and BBA64, Dps, VlsE, lipoproteins, Lp6.6, LA7, BptA, BBA07, bbe31, BbCRASP protein, BB0323, BBA52, BBA64, BmtA (BB0219), enzymes in Borrelia burgdorferi, BB0646 Tick salivary gland proteins: Salp15, Salp25D, Salp20, tick histamine releasing factor, tick salivary lectin pathway inhibitor (P8), TRE31, TROSPA (tick receptor for OspA). Depending on the implementation, screening methods can use antibodies that target one or more of these unique proteins. For example, a labeled antibody can target one or more antigens from the aforementioned list of unique proteins. If the antigen is present, the antibody will bind, causing a color change in the solution. This color change will indicate to the user that the protein, and consequently Borrelia burgdorferi, is present.
[0126] The following ideas are not intended to be limited to disease vector testing kits. In non-limiting instances, for example, they could be used in home testing kits for bacteria on human skin.
[0127] Furthermore, it is conceivable that screening results could help identify Lyme disease hotspots, particularly. Detailed location information could be collected, and the data could be anonymized, analyzed, and shared with health authorities to maximize awareness and help allocate resources in relevant areas. The only information shared could be location and a positive or negative result, eliminating any need for HIPAA compliance.
[0128] It also envisions potential expanded schemes to cover other pathogens (such as viruses) (e.g., Zika virus) transmitted by disease vectors such as mosquitoes.
[0129] Fluorescent immunoassay technique: According to one or more implementation schemes, fluorescence immunoassay methods can be used to screen for disease vectors.
[0130] When ticks are found on a person or pet, they can be treated according to the apparatus and method described herein. Buffer solutions can be added before or after mechanical treatment. The user then pours a second vial containing a solution of buffer (e.g., PBS) and labeled antibodies into the first vial containing the broken tick. After a short time, if the presence of the target-specific protein supporting the persistent presence of Borrelia burgdorferi is present, the solution will change color, indicating that the tick is a carrier of Lyme disease. Figure 7 This method can be generally referenced.
[0131] The kit may include a device for treating the target disease vector as described herein, a solution buffer source for facilitating vector treatment, and a sealed dropper filled with buffer and specifically labeled antibodies. A stable base may optionally be used to hold the tick vial during screening.
[0132] According to one or more implementation schemes, a mobile phone-based companion application can use a mobile phone to identify subtle color changes in a given solution, such as... Figure 8As shown. An object containing ticks and an antibody solution will be placed inside a provided container to block out ambient light. A mobile phone with a flash and camera will be placed on top of the container. A hole will be provided for the phone's camera and flash to illuminate the contents of the container. A magnet may optionally be used to facilitate proper placement of the mobile phone. The phone will perform an initial scan of the solution, followed by an additional scan at a second time interval (e.g., after five minutes). The mobile application will compare the images to detect any color changes in the solution. It will then report to the user whether a color change has occurred in the solution. If so, the user will know that Lyme disease-causing bacteria are present in their tick sample.
[0133] Colorimetric determination: According to one or more implementation schemes, proteins supporting the persistence of Borrelia burgdorferi in tick samples can be detected by colorimetric nanoparticles.
[0134] According to one or more implementation schemes, nanoparticle (NP) labeled antibodies and / or antigen-based sensing can be implemented.
[0135] According to one or more embodiments, nanoparticles (and / or nanorods) can be used to detect different types of proteins. Some proteins support the persistence of Borrelia burgdorferi, leading to Lyme disease. The proteins may originate from either Borrelia burgdorferi proteins or tick salivary gland proteins, as discussed and identified above. This screening method is generally as follows: Figure 9 As shown in the image.
[0136] According to one or more embodiments, molecules with high affinity for representative proteins can be conjugated to nanoparticles or nanorods with inherent colorimetric properties. Upon binding, the emitted color changes due to the alteration of the medium. Advantageously, the indicated color change can be observed by the user with the naked eye using a take-home kit, thus providing a rapid method for predicting the likelihood of Lyme disease.
[0137] According to one or more embodiments, this technology comprises a detection reagent, including but not limited to nanoparticle (NP)-labeled antibodies and / or antigens, capable of sensing the presence of Borrelia burgdorferi in ticks. Antibodies and antigens can be used in a variety of systems to sense targets, including but not limited to ELISA-like lateral chromatography assays or color changes based on in-solution aggregation. It can also be used to simultaneously detect the presence of multiple bacteria and viruses.
[0138] Lateral chromatography assay of antibody-antigen based on nanoparticle labeling: According to one or more embodiments, this technology includes, but is not limited to, antigens and antibodies, which may be labeled with nanoparticles or nanorods, said nanoparticles or nanorods may be composed of, but not limited to, gold, titanium nitride, or silicon dioxide, and may or may not have additional fluorescent dye molecules, such as, but not limited to, rhodamine. These antigens may compete with potential target antigens for their respective antibodies. Potential target antigens may include, but are not limited to, bacterial surface proteins and viral proteins.
[0139] A non-limiting example that can be used is a sandwich-based lateral chromatography assay to screen for the presence of Borrelia burgdorferi. In this apparatus, a polyclonal anti-Borrelia burgdorferi antibody is used as the capture antibody and immobilized on an LFA as a test line. Using a polyclonal Ab as the capture antibody provides high affinity for the target antigen and the ability to recognize multiple epitopes on the antigen, increasing the chance of capturing the antigen as it flows through. Monoclonal antibodies or combinations of monoclonal antibodies can also be used as capture antibodies. Targets will include OspA (if not targeted by a signaling antibody), the outer surface protein BG, FlaB (if the sample is first lysed to release its internal proteins from Borrelia burgdorferi), BBA64, or BBK32. There are two main reasons for using monoclonal Abs as capture Abs: Monoclonal Abs are produced by a single B cell clone in the laboratory, unlike polyclonal Abs produced by multiple B cell clones from different animals with different immune responses, thus resulting in batch-to-batch consistency provided by monoclonal Abs.
[0140] According to one or more non-limiting embodiments, the signaling antibody that can be used is a monoclonal anti-OspA antibody conjugated to gold nanoparticles. Using a monoclonal Ab as a signaling antibody provides the necessary specificity for the target antigen to reduce cross-linking and false positives. Furthermore, the fact that the Ab is monoclonal ensures consistency in signaling with its conjugation to AuNP. OspA was chosen as a target surface protein on Borrelia burgdorferi due to several factors. It is one of the most studied surface proteins of Borrelia burgdorferi and has been a common target in vaccine research, demonstrating its stability and immunogenicity. As one of the major surface proteins of Borrelia burgdorferi, it is also highly abundant on the bacterial surface before tick feeding. Furthermore, OspA is relatively specific to the Borrelia burgdorferi species, reducing the possibility of false positives due to cross-reactivity with other bacteria. It is also highly expressed in ticks that have not yet fed or have just begun feeding, as one of its primary purposes is to attach bacteria to the midgut of the tick.
[0141] Monoclonal anti-Osp C antibodies can also be included in LFAs as additional signaling antibodies for use in parallel with OspA Abs. This is because Osp C is a surface protein of Borrelia burgdorferi that is upregulated when the tick begins feeding. If the tick is not noticed by the host and feeds for a period of time, the OspA surface protein in the bacteria begins to be downregulated (which may lead to loss of sensitivity of the LFA), while the OspC protein begins to be upregulated. This ensures that the LFA can maintain its ability to screen for the presence of Borrelia burgdorferi before and after tick feeding, providing reliable results to the user. Proteins BBA64 or BB0323 can also be used for the same purpose, i.e., they are present on the bacteria after tick feeding, in addition to being present on the bacteria before tick feeding, but neither is as abundant as OspC after feeding and there are fewer commercially available antibodies available.
[0142] Another non-limiting example of LFA screening for another bacterium could be screening for Anaplasma phagocytophilum. The capture antibody could be a polyclonal anti-anaplasma antibody (PAA) or a monoclonal anti-MSP4 antibody (MAS4). A signaling antibody conjugated to AuNP could be a monoclonal anti-MSP5 antibody (MAS5).
[0143] Another non-limiting example of LFA screening for another bacterium could be screening for the genus Babesia, including but not limited to Babesia villiformis. In LFA, the capture antibody could be a polyclonal anti-Babesia villiformis Ab, a monoclonal anti-BmSA1 Ab, or a monoclonal anti-BmRAP-1 Ab. The signaling antibody conjugated to AuNP could be a monoclonal anti-BmSA1 Ab or a monoclonal anti-BmRAP-1 Ab; neither of these is used as a capture antibody.
[0144] According to one or more embodiments, in colorimetric assays, lateral chromatography may be chosen because it clearly indicates the presence of the target antigen without the need for auxiliary methods (from no color to a visible red line), rather than changing from one color to another or using a reader to measure emission. Furthermore, lateral chromatography assays can easily allow people to see that the test is proceeding as expected by including a control line. In addition, the COVID-19 pandemic has led to the near-ubiquitous availability of contact colorimetric lateral chromatography assays, making most people very familiar with and proficient in using the technology.
[0145] According to one or more non-limiting embodiments, the signal can be detected via the LFA in about 20 minutes or less. In a non-limiting example of a Borrelia burgdorferi LFA, the size and specifications of the LFA can be adjusted to optimally screen for target bacteria. The LFA can be competitively modulated to sense Borrelia by having a larger pore size within the nitrocellulose membrane to allow larger Borrelia burgdorferi bacteria to flow through more easily. For example, while standard pore sizes are between 3-12 μm, this embodiment may involve a pore size of at least about 6-12 μm. The LFA nitrocellulose membrane can have a larger pore size to better allow Borrelia burgdorferi (5-40 μm in length, 0.2-0.5 μm in width) to migrate through the strip. The LFA can have a pore size in the range of 8-12 μm, or it can have a pore size in the range of 12-20 μm. Additionally, the sample buffer used with the LFA may include surfactants, including but not limited to Tween-20, to reduce bacterial clumping and improve flowability. The LFA may also dispose of the conjugate pad and reduce the position of the signal antibody in the sample buffer, such as Figure 10 As shown, and as Figure 11 This contrasts with the classic design of the LFA shown.
[0146] LFAs can be used for single-use screening of multiple disease vectors carrying bacteria / viruses (pathogens; microbial agents). This multiplexing device can still be a sandwich-based LFA, but can have multiple capture antibodies immobilized on nitrocellulose strips, each located on its own strip. The conjugation pad or sample buffer can contain multiple different signal antibodies, all bound to AuNPs, such as... Figure 12 and 13 As shown. When the abrasive medium sample interacts with the signal antibody in the sample buffer or conjugation pad, the present target antigen binds to its respective signal antibody and is then immobilized on the correct respective capture antibody line. Antigen-antibody pairing can be used to test for dominant pathogenic bacteria / viruses in single or multiple disease vectors in the same sample. In non-limiting examples, Borrelia burgdorferi, Anaplasma phagocytophilum, and Babesia voles can be tested in a single multiplexed strip having antibody-antigen sandwich pairs as described above.
[0147] According to one or more embodiments, the concentration of the antibody bound to the NP can be optimized such that the NP is at a visible optical density (OD), but not so concentrated that the desired concentration of the monoclonal antibody is economically infeasible. The optimal balance between the NP OD and the amount of antibody bound to the NP allows for visual inspection and appropriate detection of bacteria according to various embodiments. When a signal antibody is generated by conjugating the antibody to AuNP, the antibody-to-AuNP concentration ratio can be between 20 μg / mL and 120 μg / mL, and between 2 and 20 OD. Additionally, the concentration of the signal antibody in the LFA kit sample buffer can be approximately 4 μg / mL, ranging from 1 to 10 μg / mL. In at least some non-limiting embodiments, a concentration of approximately 40 μg / mL can produce the strongest positive signal.
[0148] According to one or more embodiments, a unique method for detecting the presence of *Borrelia burgdorferi* (OspA is a surface protein of *Borrelia burgdorferi*) using lateral chromatography with the simultaneous use of an anti-*Borrelia burgdorferi* polyclonal antibody and an anti-OspA antibody is disclosed. The polyclonal *Borrelia burgdorferi* antibody targets proteins with molecular weights of 83 kDa, 41 kDa, 34 kDa, and 31 kDa found on the outer membrane of *Borrelia burgdorferi*, and additional low-MW bands are found inside / on *Borrelia burgdorferi*. The 31 kDa protein bound by the polyclonal antibody is the same OspA protein bound by the monoclonal antibody. The monoclonal OspA antibody is a recombinant antibody (commercially available from Absolute Antibody) that targets OspA, an outer membrane surface protein of *Borrelia burgdorferi*. Various other antibodies and combinations thereof may be implemented within the spirit of this invention.
[0149] According to one or more embodiments, the antibody (both NP-binding monoclonal signal antibody and polyclonal antibody) will be located on the LFA strip. In some embodiments, the freeze-dried reagent can be implemented with greater flexibility in the strip design.
[0150] A non-limiting example of how this can work is in a lateral flow chromatography (LFA) setting, where surface proteins of Borrelia burgdorferi, such as, but not limited to, OspA, can competitively bind to anti-OspA antibodies conjugated to the LFA with NP-labeled OspA. The less target OspA present in the sample, the more NP-labeled OspA binds to the antibody, resulting in a visible signal of variable intensity. This can lead to binary or semi-quantitative results, where a stronger line on the LFA indicates a lower level of target OspA (and therefore Borrelia burgdorferi) present in the sample.
[0151] Additionally, specific concentrations of OspA can bind to LFA, and specific concentrations of NP-labeled anti-OspA antibodies can flow down the line along with the given sample. If the sample contains OspA, those antibodies will first bind to the OspA provided by the sample, and the remaining unbound NP-labeled antibodies will bind to the LFA-conjugated OspA. The less remaining NP-labeled antibody binds to the LFA-conjugated OspA antigen, the fainter the resulting line appears, indicating the presence of more OspA in the sample. The stronger the line, the less OspA is present in the sample.
[0152] Another non-limiting example of LFA that can be used involves coating a plate with a capture antibody that specifically binds to a target antigen such as OspA. A sample containing the antigen is then added to the plate, allowing the antigen to bind to the capture antibody. Subsequently, a detection antibody that binds to OspA or another outer surface protein of Borrelia burgdorferi is added. This detection antibody is conjugated to an enzyme. The enzyme substrate is then added, producing a detectable signal, such as a color change. The intensity of the signal is measured and is proportional to the amount of antigen present in the sample.
[0153] According to one or more non-limiting embodiments, the tick breaker is a cylinder 3-4 inches high and 2-3 inches in diameter. The LFA inserted into the breaker is currently within the standard size range for LFAs: 3-5 mm wide and 50-80 mm long. Current sizes are 4 mm and 55 mm in length, but the length of the LFA can be increased if necessary to ensure it extends sufficiently beyond the top of the tick breaker and that the positive signal line is clearly visible.
[0154] According to one or more embodiments, when preparing the "signal antibody," the antibody (anti-OspA Ab) is typically conjugated to gold nanoparticles (AuNP). The ratio of OspA Ab to AuNP can be 40 μg / mL to 10 μg OD. After preparation, the signal antibody is pipetted into the sample buffer at, for example, a 1:10 ratio (10 μL signal antibody per 100 μL sample buffer), so that the final concentration of the signal Ab is 4 μg OspA Ab / 1 mL sample solution.
[0155] Based on the aggregation mechanism of antibody-antigen labeled with nanoparticles: Another non-limiting example of how antigens can be detected by NP-labeled antibodies is through aggregation mechanisms. If an antigen such as Borrelia burgdorferi is introduced into a solution of NP-labeled antibodies, the antibody can bind to different epitopes on the antigen. This causes the antibody to aggregate and become cross-linked. These aggregated, larger particles may precipitate and / or cause color changes in solution and / or cause quenching between fluorophore-associated nanoparticles that are now close to each other, where precipitation and / or color changes indicate the presence of the antigen.
[0156] Example
[0157] Optimization of monoclonal OspA signaling antibodies (Abs) in LFA
[0158] The aim of this experiment was to determine the optimal concentration ratio of signal antibody (Ab) to 10 OD gold nanoparticles (AuNP) during AuNP Ab conjugation to generate signal Ab. Various concentrations of signal antibody (recombinant monoclonal OspA antibody) were tested, and visual analysis of their various signal intensities was evaluated. The ratios of 40, 80, and 120 μg / mL to 10 OD AuNP were tested. Specifically, signal antibody concentrations (40, 80, and 120 μg / mL) were used in samples containing *Borrelia burgdorferi*.
[0159] plan: 1. Concatenate Ab with AuNP at different ratios. a. 40ug / mL i. Add 100 μL of AuNP to 4 μL of Ab. ii. Incubate on a vertical rotator for 30 minutes. iii. Block the solution by adding 12.11 uL of 10% BSA solution. iv. Incubate for another 30 minutes on a vertical rotator. b. Repeat at 80 ug / mL and 120 ug / mL i. For 80 ug / mL, use 8 uL Ab ii. For 120 ug / mL, use 12 uL Ab 2. Perform lateral chromatographic analysis (LFA) (using dip bar test strips). a. A 4x25 mm width-to-height bound nitrocellulose membrane from a lateral chromatography initiation kit. b. Pipe 1 μL of biotin-labeled rabbit polyclonal borrerovirus antibody onto the strip (the biotin-labeled Ab is not required; unlabeled borrerovirus polyclonal Ab is recommended instead) (capture line). c. 1 μL anti-mouse monoclonal antibody (control line) d. Block with PBS containing 3% BSA, and wash with PBST (1X PBS and 0.5% Tween 20). e. Wet the edges until saturated, then immerse in BSA for 15 minutes, and wash three times with PBST for one minute each time. f. Dry in a vacuum dryer for 1 hour (until completely dry). g. Attach to a 4x62mm vinyl backing card, covering an approximately 4x15mm absorbent pad, overlapping by approximately 2-5mm to ensure proper wicking contact.
[0160] 3. Preparation of sample solutions using positive spirochetal samples and signal Ab-AuNP conjugates.
[0161] a. A total of four sample solutions were measured.
[0162] i. Three samples, each with signal Ab concentrations of 40, 80, and 120 ug / mL.
[0163] ii. One “negative” sample, containing no borborygmus.
[0164] The relevant data is presented in Figure 14 This reflects the relationship between the concentration of various signal antibodies and the intensity of LFA positive signals. Red dots indicate the presence of *Borrelia burgdorferi* as a positive signal. The red line at the bottom of each LFA strip matches the height of the LFA in contact with the sample solution surface and indicates *Borrelia burgdorferi* signal Ab-AuNP conjugates that are too large to flow upwards along the test strip. A signal Ab of 40 ug / mL and 10 OD AuNP produce the strongest positive signal.
[0165] Confirming a positive correlation between Borrelia burgdorferi concentration and signal intensity
[0166] An experiment was conducted to confirm that LFA gave a less bright positive signal in the case of diluted concentrations of Borrelia burgdorferi in the sample, showing a positive qualitative correlation between the concentration of Borrelia burgdorferi and the signal intensity.
[0167] The aim of the experiment was to verify a direct correlation between the concentration of *Borreya burgdorferi* and the signal intensity of the LFA on the test strip. The LFA was screened for the presence of *Borreya burgdorferi* using a polyclonal anti-*Borreya burgdorferi* antibody as the capture antibody and an AuNP-labeled anti-OspA antibody as the signal antibody. If the sandwich assay correctly captures *Borreya burgdorferi* using the given capture and signal antibodies, a decrease in the concentration of *Borreya burgdorferi* in the sample should correlate with a decrease in the positive signal presented on the LFA. A series of dilutions from 1:1 to 1:1000 were prepared, and a copy of the LFA was inserted into each dilution. One factor that could affect the experiment is the potential cross-linking at the contact point between the LFA and the sample solution, where the cross-linked *Borreya burgdorferi*-labeled signal antibody is too large to migrate upwards along the strip, potentially affecting the signal intensity of each strip differently.
[0168] LFA Production Pipe 1 μL of biotin-labeled rabbit polyclonal anti-Treponema pallidum antibody onto the strip (the biotin-labeled antibody is not required; unlabeled anti-Treponema pallidum polyclonal antibody is recommended instead) (capture line). 1 uL anti-mouse monoclonal antibody (control line) Block with PBS containing 3% BSA, and wash with PBST (1X PBS and 0.5% Tween 20). Wet the edges until saturated, then immerse in BSA for 15 minutes, and wash three times with PBST for one minute each time. Dry in a vacuum dryer for 1 hour (until completely dry). Attach to a 4x62mm vinyl backing card, covering approximately a 4x15mm absorbent pad, overlapping by approximately 2-5mm to ensure proper wicking contact.
[0169] Each attached AuNP-Ab conjugation SOP contains an OspA monoclonal Ab and an AuNP conjugation. Brief process: ○ Dilute AuNP to 10 OD ○ For every 100 μL of AuNP 10OD, pipette 4 μL of antibody. ○ Incubate for 30 minutes on a vertical rotator. ○ Block with 1% BSA ○ Incubate for 30 minutes on a vertical rotator.
[0170] Detection dilution of Borrelia burgdorferi Current optimized standard sample solution:
[0171] Test samples containing diluted Borrelia burgdorferi: ○ 1:1 20uL Borrelia burgdorferi ○ 1:2 10 μL Borrelia burgdorferi, 10 μL H2O ○ 1:5 4 μL Borrelia burgdorferi, 16 μL H2O ○ 1:10 4 μL Borrelia burgdorferi, 36 μL H2O ○ 1:100 12uL / 1:10 solution, 108uL H2O ○ 1:1K 12uL / 1:100 saline solution, 108uL H2O Prepare samples by replacing 20 μL of the "heat-treated Borrelia burgdorferi sample (positive control)" + 1 negative control sample without Borrelia burgdorferi with 20 μL of each of the diluents listed above. Incubate for 10 minutes Transfer to a well plate and insert an LFA, then measure at 20 minutes.
[0172] The results are presented in Figure 15 From left to right: 1x, 2x, 5x, 10x, 100x, and 1000x dilutions of *Borrelia burgdorferi* samples. Well H7 on the far right is the negative control.
[0173] It was observed that the signal intensity weakened as the *Borrelia burgdorferi* sample became more diluted. Clear qualitative results were observed, showing a positive correlation between *Borrelia burgdorferi* concentration and positive signal intensity. It is also noteworthy that the "bottom red line" indicates that *Borrelia burgdorferi*-signal Abs are undergoing cross-linking, or that most *Borrelia burgdorferi*-signal Ab conjugates are too large to migrate upwards along the strip.
[0174] AuNP-OspA antibody signaling antibody conjugation
[0175] Gold nanoparticle (AuNP)-labeled anti-OspA antibodies are not readily available commercially. The following is a non-restrictive standard operating procedure (SOP) for preparing AuNP-labeled anti-OspA Abs for LFA at a concentration ratio of 40 μg / mL OspA Ab / 10 OD AuNP. Previous experiments have established pH 8.0 as the optimal pH for Ab conjugation to AuNP, and have also established 40 μg / mL Ab to 10 OD AuNP as the optimal concentration ratio for LFA.
[0176] 1. Dilute the 20 OD Au solution in stock to produce 200 μL of 10 OD: Material: 20 mM citrate, pH 5.0 0.2 mM citrate solution Au solution 20 OD
[0177] Procedure: Individually, a stock solution of 0.2 mM citrate was prepared by diluting 20 mM citrate in diH2O at a ratio of 1 / 100. Add 100 μL of Au solution OD 20 to a new Eppendorf tube. Add 1 μL of 20 mM citrate buffer to the Eppendorf tube (to generate 20 OD Au in 0.2 mM citrate solution). Add 99 μL of 0.2 mM citrate solution to obtain 200 μL of 10 OD Au.
[0178] 2. Join Ab to AuNP
[0179] Material: 4uL anti-OspA mouse monoclonal Ab 5 uL 100 mM phosphate buffer 8.0 100 μL 10 OD Au solution 10% BSA in H2O
[0180] From empty Eppendorf tube X 2 Add 5 μL of 100 mM phosphate buffer (pH 8.0) to a new empty EPPENDORF tube. Then 4 uL Ab Then add 100 μL of 10 OD AuNP aliquot sample. Gently tap the mixture with your fingers, then place it on a vertical swivel to incubate / mix for the next 30 minutes.
[0181] After incubation for 30 minutes, add 10.9 μL of 10% BSA in H2O to make 1% BSA in the solution. Incubate for another 30 minutes on a vertical rotator. Two vials were produced, each containing 100 μL of AuNP-labeled OspA Ab signaling antibody, which can be used in LFA.
[0182] The wording and terminology used herein are for descriptive purposes and should not be considered restrictive. As used herein, the term "plurality" refers to two or more articles or components. Whether in the written description or claims, the terms "comprising," "including," "carrying," "having," "containing," and "involving" are open-ended terms, meaning "including but not limited to." Therefore, the use of such terms is intended to cover items listed below and their equivalents, as well as additional items. For the purposes of the claims, only the transitional phrases "consisting of" and "consisting essentially of" are closed or semi-closed transitional phrases, respectively. The use of ordinal numbers such as "first," "second," "third," etc., to modify claim elements in claims does not in itself imply any priority, order, or hierarchy of one claim element relative to another claim element, nor does it indicate the chronological order in which the steps of the method are performed. Rather, it is merely used as a label to distinguish one claim element with a certain name from another element with the same name (but using an ordinal number), thereby differentiating the claim elements.
[0183] Therefore, having described several aspects of at least one embodiment, it should be understood that various changes, modifications, and improvements will readily occur to those skilled in the art. Any feature described in any embodiment may be included in or substitute for any feature in any other embodiment. Such changes, modifications, and improvements are intended to be part of this disclosure and are intended to be within the scope of the invention. Therefore, the foregoing description and drawings are merely exemplary.
[0184] Those skilled in the art will understand that the parameters and configurations described herein are exemplary, and actual parameters and / or configurations will depend on the specific application in which the disclosed methods and materials are used. Those skilled in the art will also recognize or be able to determine equivalents of the specific embodiments disclosed, using no more than conventional experiments.
[0185] What is being protected is...
Claims
1. An apparatus for treating disease vectors for screening, comprising: A container, the container defining a breakage recess, the breakage recess being constructed and arranged for receiving disease vectors for treatment; A cap, configured to create a self-contained system when securely engaged with the container and not reopen, while remaining rotatable relative to the container to facilitate the handling of the disease vector within the self-contained system; and A breaking element extends from the cap into the container and is configured to engage with the breaking recess via rotation of the cap to treat the disease vector.
2. The apparatus according to any one of the preceding claims, wherein processing the disease vector includes at least partially breaking down the disease vector.
3. The apparatus according to any one of the preceding claims, wherein the self-contained system is configured to apply mechanical force to the disease vector.
4. The apparatus according to any one of the preceding claims, wherein the self-contained system is configured to apply mechanical force to the disease vector along two axes.
5. The apparatus according to any one of the preceding claims, wherein at least one of the breaking recess and the breaking element defines a surface roughness to facilitate the treatment of the disease vector.
6. The apparatus according to any one of the preceding claims, wherein the crushing element comprises a crushing head connected to the crushing tool.
7. The apparatus according to any one of the preceding claims, wherein the breaking element includes one or more contact portions to facilitate the treatment of the disease vector.
8. The apparatus according to any one of the preceding claims, wherein the container is further configured to receive fluid to facilitate screening for treated disease vectors.
9. The apparatus according to any one of the preceding claims, wherein the apparatus further comprises a fluid chamber.
10. The apparatus according to any one of the preceding claims, wherein the fluid chamber is contained within the cover or container.
11. The apparatus according to any one of the preceding claims, wherein the apparatus further comprises a separation mechanism to facilitate downstream disease vector screening.
12. The apparatus according to any one of the preceding claims, wherein the apparatus is capable of being connected to a measuring device.
13. The apparatus according to any one of the preceding claims, wherein the measuring apparatus does not involve DNA-based measurements.
14. The apparatus according to any one of the preceding claims, wherein the apparatus is configured to receive a assay strip to facilitate disease vector screening.
15. The apparatus according to any one of the preceding claims, wherein screening for the disease vector involves a fluorescent immunoassay.
16. The apparatus according to any one of the preceding claims, wherein the measuring apparatus is a colorimetric measuring device.
17. The apparatus according to any one of the preceding claims, wherein screening for the disease vector involves nanoparticle (NP) labeled antibodies and / or antigen-based sensing.
18. The apparatus according to any one of the preceding claims, wherein the assay apparatus uses both an anti-Breorhynchus burgdorferi polyclonal antibody and an anti-OspA antibody.
19. The device according to any one of the preceding claims, wherein the concentration of the signaling antibody is about 40 ug / mL.
20. The device according to any one of the preceding claims, wherein the device is a tick screening device intended for home use.
21. A lateral chromatographic assay (LFA) for screening disease vectors, comprising: Anti-Bretorius polyclonal antibody and anti-OspA antibody.
22. A reagent kit comprising: An apparatus for treating disease vectors according to any one of the preceding claims.
23. The kit according to any one of the preceding claims further comprises a buffer solution source.
24. The kit according to any one of the preceding claims further comprises a labeled antibody source.
25. The kit according to any one of the preceding claims, wherein the labeled antibody source comprises a sealed dropper containing a buffer solution of the labeled antibody.
26. The kit according to any one of the preceding claims further includes a measuring device.
27. The kit according to any one of the preceding claims, wherein the assay device is based on the sensing assay of antibodies and / or antigens.
28. The kit according to any one of the preceding claims, wherein the assay device is a fluorescence immunoassay.
29. The kit according to any one of the preceding claims, wherein the measuring device is a colorimetric measuring device.
30. The kit according to any one of the preceding claims, wherein the assay device is a lateral chromatographic assay (LFA).
31. The kit according to any one of the preceding claims, wherein the assay device relates to an LFA test strip.
32. The kit according to any one of the preceding claims, wherein the assay device uses both an anti-Breorhynchus burgdorferi polyclonal antibody and an anti-OspA antibody.
33. The kit according to any one of the preceding claims, wherein the assay device uses an anti-Breorhynchus burgdorferi polyclonal antibody, an anti-OspA antibody, and an anti-OspC antibody.
34. The kit according to any one of the preceding claims, wherein the concentration of the signal antibody-AuNP present in the LFA sample buffer is about 4 ug / mL.
35. The kit according to any one of the preceding claims, wherein the conjugation ratio of the signal antibody to AuNP is approximately 40 ug / mL per 10 OD.
36. The kit according to any one of the preceding claims, wherein the assay device uses a unique capture-signal antibody sandwich combination against each tested bacterium to screen for multiple vector-borne diseases in a single sample.
37. The kit according to any one of the preceding claims, wherein the LFA test strip is defined by an average pore size of at least about 6-12 μm.
38. The kit according to any one of the preceding claims, wherein the assay screens for proteins associated with Anaplasma phagocytophilum or Babesia voles.
39. The kit according to any one of the preceding claims, wherein the LFA test strip does not include the conjugate pad on which the signal antibody is immobilized.
40. The kit according to any one of the preceding claims, wherein the signaling antibody is present in a buffer solution.
41. The kit according to any one of the preceding claims, wherein the assay is based on aggregation.
42. The kit according to any one of the preceding claims, further comprising a base configured to stabilize the container during treatment of the disease vector.
43. The kit according to any one of the preceding claims, wherein the kit is intended for home use.
44. The kit according to any one of the preceding claims, wherein the kit is a Lyme disease screening kit.
45. A method for screening disease vectors, comprising: The disease vector is treated with the apparatus of claim 1 to produce a solution; and The solution is subjected to assays to assess the presence or absence of pathogenic pathogens.
46. The method according to any one of the preceding claims, wherein treating the disease vector involves applying mechanical force along two axes.
47. The method according to any one of the preceding claims, wherein the assay is not a DNA-based assay.
48. The method according to any one of the preceding claims, wherein the determination screens for target proteins associated with the pathogenic pathogen.
49. The method according to any one of the preceding claims, wherein the pathogenic pathogen is associated with Lyme disease, babesiosis, erythrozoonosis, Rocky Mountain spotted fever, anaplasmosis, southern tick-associated rash, tick-borne relapsing fever, and tularemia.
50. The method according to any one of the preceding claims, wherein the target protein is associated with Lyme disease pathogens.
51. The method according to any one of the preceding claims, wherein the target protein is associated with Borrelia burgdorferi.
52. The method according to any one of the preceding claims, wherein the determination targets Borrelia burgdorferi protein.
53. The method according to any one of the preceding claims, wherein the determination targets outer surface protein A (OspA).
54. The method according to any one of the preceding claims, wherein the determination targets tick salivary gland proteins.
55. The method according to any one of the preceding claims, wherein the assay is based on the sensing of antibodies and / or antigens.
56. The method according to any one of the preceding claims, wherein the determination is a lateral chromatographic assay (LFA).
57. The method according to any one of the preceding claims, wherein the determination is an aggregation-based determination.
58. The method according to any one of the preceding claims, wherein the determination further screens for a second target protein associated with a second pathogenic bacterium.
59. Any lateral chromatographic assay (LFA) used for screening disease vectors as described herein.
60. The LFA according to any one of the preceding claims, wherein the LFA screens for target proteins associated with Lyme disease pathogenic bacteria.
